Idelalisib, also known as CAL-101, has been approved by the FDA as the first-in-class PI3K inhibitor for hematological cancer treatment [99], but the possibility of using idelalisib in HNSCC remains unestablished. The gene discussed is PIK3CD; the disease is head and neck squamous cell carcinoma.